Ferring Signs Global Agreement to Commercialise Novel Gene Therapy for Bladder Cancer Patients
Ferring Pharmaceuticals today announced the signing of an agreement giving the company the option to secure global commercialisation rights to nadofaragene firadenovec/Syn3 (rAd-IFN/Syn3), a novel gene therapy being developed by FKD Therapies Oy (FKD) as a treatment for patients with high-grade non-muscle invasive bladder cancer (NMIBC), who are unresponsive to Bacillus Calmette-Guérin (BCG) therapy. This option is exercisable on marketing approval from the US FDA. Ferring will create a new US oncology division with the specialist knowledge and presence to introduce novel advanced therapies to the market.
rAd-IFN/Syn3 is currently undergoing Phase 3 development in the US under the sponsorship of Finnish gene therapy specialists FKD. The results of the earlier Phase 2 trial, published in the Journal of Clinical Oncology, reported 35% of BCG unresponsive NMIBC bladder cancer patients given one dose of rAd-IFN/Syn3 every three months, were free of high-grade disease at one year1. The ongoing Phase 3 study is designed to establish the efficacy and safety of the product. rAd-IFN/Syn3 has been awarded Fast Track and Breakthrough Therapy designations by the FDA.
“We are excited about the potential to commercialise rAd-IFN/Syn3, a novel gene therapy for bladder cancer patients,” said Michel Pettigrew, President of the Executive Board and Chief Operating Officer, Ferring Pharmaceuticals. “The gene therapy sector is growing rapidly and building a presence in this specialised area is a very positive opportunity for Ferring.”
Bladder cancer is one of the most frequently occurring cancers with an estimated 430,000 new cases being reported worldwide each year2. It is the fourth most common cancer in men in the US3 and is the most expensive cancer to treat on a life-time basis, with a high burden on patients, their relatives and healthcare systems4. In high-grade NMIBC patients, BCG is the gold standard treatment and although effective, over 60% of cases eventually re-occur5, 6. The outcome for such patients is poor, with total cystectomy (complete removal of the bladder) to prevent the cancer spreading to other organs generally being the next treatment option. As such, the BCG unresponsive population is one of high unmet clinical need.
“Today, bladder cancer patients have very limited medical options and new treatments that delay or prevent total removal of the bladder and improve clinical outcomes are urgently needed for patients,” said Professor Klaus Dugi, Chief Medical Officer, Ferring Pharmaceuticals. “Phase 2 clinical results for rAd-IFN/Syn3 were very encouraging and we look forward to the Phase 3 data.”
Gene therapy is one of a new class of therapeutic treatments known as advanced therapy medicinal products. rAd-IFN/Syn3 is built on adenoviral vector technology, a non-integrating vector, and results in enhanced expression of the therapeutic protein interferon alfa 2b. To date, it has completed three clinical trials in the US.
rAd-IFN/Syn3 (nadofaragene firadenovec/Syn3) is an investigational gene therapy consisting of an adenovirus containing the gene interferon alfa-2b. It is administered by catheter into the bladder, where the virus enters the cells of the bladder wall. Inside the cells, the virus breaks down leaving the active gene to do its work. The internal gene/DNA machinery of the cells picks up the gene and translates its DNA sequence, resulting in the cells secreting high quantities of interferon alfa-2b protein, a naturally occurring protein the body uses to fight cancer. This novel gene therapy approach turns the patient's own bladder wall cells into multiple interferon microfactories, enhancing the body's natural defences against the cancer. The Phase 3 trial for rAd-IFN/Syn3 opened in 2016 with up to 150 patients to be enrolled across 35 centers in the US.
About FKD Therapies Oy
FKD Therapies Oy is a gene therapy company, located in Kuopio, Finland and is the sponsor and developer of rAd-IFN/Syn3.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalised healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.
# # #
1 Shore ND, Boorjian AS, Canter KD, Ogan K, Karsh IL, Downs MT, et al. Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol [Internet]. 2017 October [cited 2018 Mar 19]; 35(30):3410-3416. Available from http://ascopubs.org/doi/full/10.1200/JCO.2017.72.3064
2 Antoni S, Ferlay J, Soerjomataram I, Znaor A, Ahmedin J, Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol [Internet]. 2017 Jan [cited 2018 Mar 19]; 71(1):96-108. Available from: http://www.europeanurology.com/article/S0302-2838(16)30280-9/fulltext
3 Colorectal cancer can be prevented. Get screened [Internet]. United States: American Cancer Society; 2018. Key Statistics for Bladder Cancer; 2018 Jan 4 [cited 2018 March 19]. Available from: https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html
4 Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, et al. Economic aspects of bladder cancer: what are the benefits and costs?. World J Urol [Internet]. 2009 Mar [cited 2018 Mar 19]; 27(3): 295-300. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694315/
5 Maruf M, Brancato S, Agarwal P. Non invasive bladder cancer: a primer on immunotherapy. Cancer Biol Med [Internet]. 2016 Jun [cited 2018 March 19]; 13(2): 194–205. Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944546/
6 Derré L, Cesson V, Lucca I, Cerantola Y, Valerio M 1, Fritschi U, et al. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients. Clin Cancer Res [Internet]. 2017 Feb [cited 2018 Mar 19]; 23(3): 717-725. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27521445
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Lion/Gem Luxembourg 3 S.a.r.l. Announce Second Quarter Results for FY 201824.5.2018 11:00 | Tiedote
The Second Quarter results for FY18 for Lion/Gem Luxembourg 3 S.a.r.l. (associated with Young’s Seafood Limited) will be made available on our Investor Relations website on May 24, 2018. The Second Quarter results call for investors that accompanies this information is scheduled to take place at 13:00 BST on May 24, 2018. The Second Quarter covers the quarter to 31 March 2018; the financial year end for Lion/Gem Luxembourg 3 S.a.r.l. is September 30, 2018. For further information: If you are an investor or a potential investor in the 8¼%/ 9% Senior PIK Notes due 2019, of Lion/Gem Luxembourg 3 S.a.r.l., and would like access to this information, please register your interest on our Investor Relations website: https://youngsseafood.co.uk/investors/. If you have any questions about the registration process or need further information, please do not hesitate to contact Nicholas Donnelly, Communications Manager at Young’s Seafood: firstname.lastname@example.org This announcement cont
Rakuten Announces Signing of Andrés Iniesta to Vissel Kobe24.5.2018 10:55 | Tiedote
Rakuten Vissel Kobe, Inc., a Rakuten Group company, today announced that Andrés Iniesta will join Vissel Kobe, the much-loved Western Japan football club, after an historic career at FC Barcelona, one of the most iconic and beloved football clubs in the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180524005463/en/ Since the beginning of his professional career with FC Barcelona in 2002, Iniesta has not only become one of the top players in the world, he is also renowned for his embodiment of the philosophy and values of the iconic club, with his commitment to teamwork and beautiful play. With a social media presence that includes over 74 million followers, Iniesta is also known as a global influencer. Iniesta developed his football career through the FC Barcelona cantera, the club’s unique youth league system that fosters young players, and his addition to Vissel Kobe is not only expected to draw in fans to see his
Poseidon Foundation Launches First Retail Platform That Allows Consumers to Support Climate Action Using Blockchain Technology24.5.2018 10:13 | Tiedote
The world’s first retail platform that connects consumers to their own carbon footprint has been launched in London by non-profit ogranisation the Poseidon Foundation (“Poseidon”). Poseidon’s platform uses blockchain technology to integrate carbon markets into transactions at the point-of-sale, giving retailers and their customers the opportunity to support forestry conservation projects around the world when they buy and sell everyday items, and in turn support action on climate change. The retail platform launched on 1st May, and a pilot is currently underway at Ben & Jerry’s newest ice cream Scoop Shop in Wardour Street, London. For every scoop of ice cream sold the values-led ice cream company is contributing towards carbon credits from a forest conservation project in Peru, and is offering their customers the opportunity to join them in taking action at the point of sale, using blockchain technology. Ben & Jerry’s has been vocal for many years on the issue of climate justice, incl
GSMA Announces New Events and Programmes Taking Place at Mobile World Congress Shanghai 201824.5.2018 10:00 | Tiedote
The GSMA today provided further details on the array of events and programmes that will be available to attendees at the 2018 GSMA Mobile World Congress Shanghai, including partner and co-located events; GSMA Forums, Seminars and Workshops; and Partner Programmes. Mobile World Congress Shanghai will be held 27-29 June at the Shanghai New International Expo Centre (SNIEC). “We’ve expanded the number of programmes and events at Mobile World Congress Shanghai, featuring everything from sports and fitness to service robots to the intersection of art and innovation, and beyond,” said Michael O’Hara, Chief Marketing Officer, GSMA. “We have a very exciting event lined up and we are looking forward to bringing the mobile world together in Shanghai next month.” New Details on Partner and Co-located Events at Mobile World Congress Shanghai The GSMA today provided an update on the partner and co-located events that will be held concurrently with Mobile World Congress Shanghai, offering attendees
FUELSAVE GmbH: FS MARINE+ is Revolutionizing Shipping Efficiency, Helping Ship Operators to Become Cleaner & More Profitable for a Unique Win-Win24.5.2018 10:00 | Tiedote
FUELSAVE GmbH is launching a revolutionary efficiency enhancement technology for Diesel (MGO / MDO) and Heavy-Fuel-Oil (HFO) engines on maritime vessels, which has been field & laboratory proven to significantly reduce fuel consumption and save contractually guaranteed 10% of the overall fuel costs, to lower the OPEX and increase profitability, while significantly reducing emissions ( CO2 by 10-15%, FSN by 40%, NOx by 30-70% etc.) for saving the environment and reducing Green House Gases (GHG) with a visible exhaust smoke reduction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180524005120/en/ FS MARINE+ Next Generation Efficiency Enhancement for Maritime Vessels The company's breakthrough unit, called FS MARINE+ is an engine efficiency enhancement solution, with an onboard hydrogen syngas generator, which combines different processes of gas and liquid water methanol injection to significantly improve combustion efficiency
Elliott Advisors (UK) Limited Statement on thyssenkrupp AG24.5.2018 09:30 | Tiedote
Further to recent media speculation, funds advised by Elliott Advisors (UK) Limited (“Elliott”) confirm that they are significant shareholders in thyssenkrupp AG (“thyssenkrupp” or the “Company”). The funds’ position in ordinary shares is such that it does not exceed, as of today, the thresholds mandating disclosure under applicable German laws. Elliott will make any disclosure regarding its holdings in the shares of thyssenkrupp no later than when and as required by German law. Elliott’s approach to its investment in thyssenkrupp is consistent with its approach to all its investments. Elliott has spent significant time and resources analysing the Company, performing exhaustive research on its prospects, competitive positioning and valuation. Elliott believes thyssenkrupp has significant scope for operational improvement which would benefit all stakeholders and looks forward to engaging in a constructive dialogue with them in the near future, including with the supervisory and manageme
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme